Standalone Q2 profit rises 60%; H1 revenue up 22% and Zettaone deal agreed

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

JUBLINGREA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.4%Reaction day

₹607.25

prior close

₹620.65

announcement price

In-mkt

timing

Nifty Smallcap 250market+2.2%+3.2% vs market

Specialty Chemicals peers, median of 100sector+1.6%+3.8% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Smallcap 250 and 3.8 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.9

10m

+1.9

15m

+2.6

30m

+3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.4+2.2+3.2+1.6+3.8

Next day

-3.0+2.5-5.5+2.0-5.0

-7.1+3.2-10.3+2.2-9.3

-7.6pendingpending+0.0-7.6

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Specialty Chemicals peers, median of 100Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board approved unaudited Q2 and half-year results. On a standalone basis, Q2 revenue rose 16.3% to INR 1,225.95 crore and net profit rose 59.9% to INR 70.4 crore. Half-year revenue rose 22.3% to INR 2,478.6 crore and net profit rose 90.8% to INR 196.62 crore; operating cash flow was positive at INR 144.26 crore. A prior-year INR 12.22 crore labour-code charge was exceptional. The company agreed to buy 40% of Zettaone for INR 189.2 crore.

Likely market impact

Profit growth and cash flow support sentiment. The INR 189.2 crore acquisition adds execution risk but may support long-term growth.